Cargando…

Near-infrared spectroscopy StO(2) monitoring to assess the therapeutic effect of drotrecogin alfa (activated) on microcirculation in patients with severe sepsis or septic shock

BACKGROUND: Sepsis is a leading cause of death despite appropriate management. There is increasing evidence that microcirculatory alterations might persist independently from macrohemodynamic improvement and are related to clinical evolution. Future efforts need to be directed towards microperfusion...

Descripción completa

Detalles Bibliográficos
Autores principales: Masip, Jordi, Mesquida, Jaume, Luengo, Cecilia, Gili, Gisela, Gomà, Gemma, Ferrer, Ricard, Teboul, Jean Louis, Payen, Didier, Artigas, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3847092/
https://www.ncbi.nlm.nih.gov/pubmed/24007807
http://dx.doi.org/10.1186/2110-5820-3-30
_version_ 1782293537827586048
author Masip, Jordi
Mesquida, Jaume
Luengo, Cecilia
Gili, Gisela
Gomà, Gemma
Ferrer, Ricard
Teboul, Jean Louis
Payen, Didier
Artigas, Antonio
author_facet Masip, Jordi
Mesquida, Jaume
Luengo, Cecilia
Gili, Gisela
Gomà, Gemma
Ferrer, Ricard
Teboul, Jean Louis
Payen, Didier
Artigas, Antonio
author_sort Masip, Jordi
collection PubMed
description BACKGROUND: Sepsis is a leading cause of death despite appropriate management. There is increasing evidence that microcirculatory alterations might persist independently from macrohemodynamic improvement and are related to clinical evolution. Future efforts need to be directed towards microperfusion monitoring and treatment. This study explored the utility of thenar muscle oxygen saturation (StO(2)) and its changes during a transient vascular occlusion test (VOT) to measure the microcirculatory response to drotrecogin alfa (activated) (DrotAA) in septic patients. METHODS: A prospective, observational study was performed in three general intensive care units at three university hospitals. We studied 58 patients with recent onset of severe sepsis or septic shock and at least two organ dysfunctions. Thirty-two patients were treated with DrotAA and 26 were not treated because of formal contraindication. StO(2) was monitored using near-infrared spectroscopy (NIRS), and VOT was performed to obtain deoxygenation (DeOx) and reoxygenation (ReOx) slopes. Measurements were obtained before DrotAA was started and were repeated daily for a 96-hour period. RESULTS: Patients’ characteristics, outcome, severity, and baseline values of StO(2), DeOx, and ReOx did not differ between groups. Treated patients significantly improved DeOx and ReOx values over time, whereas control patients did not. In treated patients, ReOx improvements were correlated to norepinephrine dose reductions. Early clinical response (SOFA improvement after 48 hours of treatment) was not associated to changes in VOT-derived slopes. In the treated group, the relative improvement of DeOx within 48 hours was able to predict mortality (AUC 0.91, p < 0.01). CONCLUSIONS: In patients with severe sepsis or septic shock, DrotAA infusion was associated with improvement in regional tissue oxygenation. The degree of DeOx amelioration after 2 days in treated patients predicted mortality with high sensitivity and specificity. Thus, StO(2) derived variables might be useful to evaluate the microcirculatory response to treatment of septic shock.
format Online
Article
Text
id pubmed-3847092
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Springer
record_format MEDLINE/PubMed
spelling pubmed-38470922013-12-06 Near-infrared spectroscopy StO(2) monitoring to assess the therapeutic effect of drotrecogin alfa (activated) on microcirculation in patients with severe sepsis or septic shock Masip, Jordi Mesquida, Jaume Luengo, Cecilia Gili, Gisela Gomà, Gemma Ferrer, Ricard Teboul, Jean Louis Payen, Didier Artigas, Antonio Ann Intensive Care Research BACKGROUND: Sepsis is a leading cause of death despite appropriate management. There is increasing evidence that microcirculatory alterations might persist independently from macrohemodynamic improvement and are related to clinical evolution. Future efforts need to be directed towards microperfusion monitoring and treatment. This study explored the utility of thenar muscle oxygen saturation (StO(2)) and its changes during a transient vascular occlusion test (VOT) to measure the microcirculatory response to drotrecogin alfa (activated) (DrotAA) in septic patients. METHODS: A prospective, observational study was performed in three general intensive care units at three university hospitals. We studied 58 patients with recent onset of severe sepsis or septic shock and at least two organ dysfunctions. Thirty-two patients were treated with DrotAA and 26 were not treated because of formal contraindication. StO(2) was monitored using near-infrared spectroscopy (NIRS), and VOT was performed to obtain deoxygenation (DeOx) and reoxygenation (ReOx) slopes. Measurements were obtained before DrotAA was started and were repeated daily for a 96-hour period. RESULTS: Patients’ characteristics, outcome, severity, and baseline values of StO(2), DeOx, and ReOx did not differ between groups. Treated patients significantly improved DeOx and ReOx values over time, whereas control patients did not. In treated patients, ReOx improvements were correlated to norepinephrine dose reductions. Early clinical response (SOFA improvement after 48 hours of treatment) was not associated to changes in VOT-derived slopes. In the treated group, the relative improvement of DeOx within 48 hours was able to predict mortality (AUC 0.91, p < 0.01). CONCLUSIONS: In patients with severe sepsis or septic shock, DrotAA infusion was associated with improvement in regional tissue oxygenation. The degree of DeOx amelioration after 2 days in treated patients predicted mortality with high sensitivity and specificity. Thus, StO(2) derived variables might be useful to evaluate the microcirculatory response to treatment of septic shock. Springer 2013-09-04 /pmc/articles/PMC3847092/ /pubmed/24007807 http://dx.doi.org/10.1186/2110-5820-3-30 Text en Copyright © 2013 Masip et al.; licensee Springer. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Masip, Jordi
Mesquida, Jaume
Luengo, Cecilia
Gili, Gisela
Gomà, Gemma
Ferrer, Ricard
Teboul, Jean Louis
Payen, Didier
Artigas, Antonio
Near-infrared spectroscopy StO(2) monitoring to assess the therapeutic effect of drotrecogin alfa (activated) on microcirculation in patients with severe sepsis or septic shock
title Near-infrared spectroscopy StO(2) monitoring to assess the therapeutic effect of drotrecogin alfa (activated) on microcirculation in patients with severe sepsis or septic shock
title_full Near-infrared spectroscopy StO(2) monitoring to assess the therapeutic effect of drotrecogin alfa (activated) on microcirculation in patients with severe sepsis or septic shock
title_fullStr Near-infrared spectroscopy StO(2) monitoring to assess the therapeutic effect of drotrecogin alfa (activated) on microcirculation in patients with severe sepsis or septic shock
title_full_unstemmed Near-infrared spectroscopy StO(2) monitoring to assess the therapeutic effect of drotrecogin alfa (activated) on microcirculation in patients with severe sepsis or septic shock
title_short Near-infrared spectroscopy StO(2) monitoring to assess the therapeutic effect of drotrecogin alfa (activated) on microcirculation in patients with severe sepsis or septic shock
title_sort near-infrared spectroscopy sto(2) monitoring to assess the therapeutic effect of drotrecogin alfa (activated) on microcirculation in patients with severe sepsis or septic shock
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3847092/
https://www.ncbi.nlm.nih.gov/pubmed/24007807
http://dx.doi.org/10.1186/2110-5820-3-30
work_keys_str_mv AT masipjordi nearinfraredspectroscopysto2monitoringtoassessthetherapeuticeffectofdrotrecoginalfaactivatedonmicrocirculationinpatientswithseveresepsisorsepticshock
AT mesquidajaume nearinfraredspectroscopysto2monitoringtoassessthetherapeuticeffectofdrotrecoginalfaactivatedonmicrocirculationinpatientswithseveresepsisorsepticshock
AT luengocecilia nearinfraredspectroscopysto2monitoringtoassessthetherapeuticeffectofdrotrecoginalfaactivatedonmicrocirculationinpatientswithseveresepsisorsepticshock
AT giligisela nearinfraredspectroscopysto2monitoringtoassessthetherapeuticeffectofdrotrecoginalfaactivatedonmicrocirculationinpatientswithseveresepsisorsepticshock
AT gomagemma nearinfraredspectroscopysto2monitoringtoassessthetherapeuticeffectofdrotrecoginalfaactivatedonmicrocirculationinpatientswithseveresepsisorsepticshock
AT ferrerricard nearinfraredspectroscopysto2monitoringtoassessthetherapeuticeffectofdrotrecoginalfaactivatedonmicrocirculationinpatientswithseveresepsisorsepticshock
AT tebouljeanlouis nearinfraredspectroscopysto2monitoringtoassessthetherapeuticeffectofdrotrecoginalfaactivatedonmicrocirculationinpatientswithseveresepsisorsepticshock
AT payendidier nearinfraredspectroscopysto2monitoringtoassessthetherapeuticeffectofdrotrecoginalfaactivatedonmicrocirculationinpatientswithseveresepsisorsepticshock
AT artigasantonio nearinfraredspectroscopysto2monitoringtoassessthetherapeuticeffectofdrotrecoginalfaactivatedonmicrocirculationinpatientswithseveresepsisorsepticshock